Clearside Biomedical (CLSD) News Today → The most important AI company you've never heard of (From Manward Press) (Ad) Free CLSD Stock Alerts $1.32 0.00 (0.00%) (As of 11:09 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 2:42 AM | americanbankingnews.comClearside Biomedical, Inc. (NASDAQ:CLSD) Forecasted to Post FY2024 Earnings of ($0.59) Per ShareMay 15 at 8:27 PM | marketbeat.comInsider Buying: Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Acquires 7,813 Shares of StockClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) Director Benjamin R. Yerxa purchased 7,813 shares of the company's stock in a transaction that occurred on Wednesday, May 15th. The stock was acquired at an average cost of $1.31 per share, with a total value of $10,235.03. Following the transaction, the director now directly owns 17,957 shares of the company's stock, valued at $23,523.67. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.May 15 at 8:12 AM | marketbeat.comFY2024 EPS Estimates for Clearside Biomedical, Inc. (NASDAQ:CLSD) Cut by AnalystClearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) - Research analysts at HC Wainwright dropped their FY2024 earnings estimates for shares of Clearside Biomedical in a research report issued on Monday, May 13th. HC Wainwright analyst Y. Chen now anticipates that the company will post earningsMay 15 at 5:58 AM | americanbankingnews.comQ1 2025 Earnings Estimate for Clearside Biomedical, Inc. Issued By HC Wainwright (NASDAQ:CLSD)May 15 at 4:59 AM | americanbankingnews.comClearside Biomedical (NASDAQ:CLSD) Given Buy Rating at Needham & Company LLCMay 15 at 3:38 AM | americanbankingnews.comClearside Biomedical (NASDAQ:CLSD) Price Target Lowered to $5.00 at HC WainwrightMay 14 at 8:25 AM | marketbeat.comClearside Biomedical, Inc. to Post Q1 2025 Earnings of ($0.15) Per Share, HC Wainwright Forecasts (NASDAQ:CLSD)Clearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Clearside Biomedical in a research note issued to investors on Monday, May 13th. HC Wainwright analyst Y. Chen expects that the company wiMay 13 at 10:52 AM | markets.businessinsider.comBuy Rating for Clearside Biomedical Amid Promising CLS-AX Trial Progress and Sufficient Cash RunwayMay 13 at 8:47 AM | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $4.00 price target on shares of Clearside Biomedical in a research note on Monday.May 13 at 8:47 AM | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Price Target Cut to $5.00 by Analysts at HC WainwrightHC Wainwright cut their price objective on shares of Clearside Biomedical from $6.00 to $5.00 and set a "buy" rating on the stock in a research report on Monday.May 12, 2024 | americanbankingnews.comStockNews.com Downgrades Clearside Biomedical (NASDAQ:CLSD) to SellMay 11, 2024 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Cut to Sell at StockNews.comStockNews.com cut shares of Clearside Biomedical from a "hold" rating to a "sell" rating in a research report on Friday.May 10, 2024 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPSClearside Biomedical (NASDAQ:CLSD - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). The company had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.98 million. During the same period in the previous year, the company earned ($0.15) EPS.May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed: Clearside Biomedical’s Promising Phase 2b Odyssey Trial and Strategic CMO Hire Signal Strong OutlookMay 10, 2024 | finance.yahoo.comClearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 Clearside Biomedical Inc Earnings CallMay 10, 2024 | markets.businessinsider.comBuy Rating on Clearside Biomedical: Anticipating ODYSSEY Trial Success and Market Growth PotentialMay 9, 2024 | globenewswire.comClearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comClearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences ConferenceMay 7, 2024 | insidertrades.com3 Penny Stocks That Insiders Are Buying (CLSD)April 30, 2024 | globenewswire.comClearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024April 21, 2024 | seekingalpha.comCLSD Clearside Biomedical, Inc.April 16, 2024 | globenewswire.comClearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of DirectorsApril 15, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significant Drop in Short InterestClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) saw a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 224,300 shares, a drop of 34.0% from the March 15th total of 339,900 shares. Based on an average daily volume of 353,400 shares, the short-interest ratio is presently 0.6 days.April 11, 2024 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $4.00 target price on shares of Clearside Biomedical in a research note on Thursday.April 2, 2024 | globenewswire.comClearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 30, 2024 | marketbeat.comShort Interest in Clearside Biomedical, Inc. (NASDAQ:CLSD) Expands By 23.4%Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 339,900 shares, an increase of 23.4% from the February 29th total of 275,400 shares. Based on an average daily trading volume, of 339,500 shares, the days-to-cover ratio is presently 1.0 days.March 21, 2024 | insidertrades.comNgai Hang Victor Chong Buys 30,000 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) StockMarch 20, 2024 | marketbeat.comInsider Buying: Clearside Biomedical, Inc. (NASDAQ:CLSD) Insider Buys 30,000 Shares of StockClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) insider Ngai Hang Victor Chong purchased 30,000 shares of the stock in a transaction dated Wednesday, March 20th. The stock was acquired at an average cost of $1.60 per share, with a total value of $48,000.00. Following the transaction, the insider now directly owns 30,000 shares in the company, valued at approximately $48,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.March 18, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Clearside Biomedical (NASDAQ:CLSD)HC Wainwright restated a "buy" rating and set a $6.00 price objective on shares of Clearside Biomedical in a report on Thursday.March 18, 2024 | globenewswire.comClearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical OfficerMarch 14, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Up 70.1% in FebruaryClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) saw a significant growth in short interest in February. As of February 29th, there was short interest totalling 275,400 shares, a growth of 70.1% from the February 14th total of 161,900 shares. Based on an average trading volume of 282,500 shares, the short-interest ratio is presently 1.0 days.March 14, 2024 | markets.businessinsider.comClearside Biomedical: Strong Buy Rating on Robust Financials and Clinical Trial ProgressMarch 14, 2024 | finance.yahoo.comClearside Biomedical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineMarch 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Clearside Biomedical on Innovative Treatments and Strong FinancialsMarch 13, 2024 | finance.yahoo.comClearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Given "Outperform" Rating at WedbushWedbush reaffirmed an "outperform" rating and set a $4.00 price target (down previously from $5.00) on shares of Clearside Biomedical in a report on Wednesday.March 12, 2024 | benzinga.comClearside Biomedical: Q4 Earnings InsightsMarch 12, 2024 | finance.yahoo.comClearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ...March 12, 2024 | globenewswire.comClearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 11, 2024 | benzinga.comPreview: Clearside Biomedical's EarningsMarch 1, 2024 | finance.yahoo.comClearside Biomedical, Inc. (CLSD)February 29, 2024 | globenewswire.comClearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024February 25, 2024 | investorplace.com7 Biotech Penny Stocks on the Verge of Clinical Trial VictoryFebruary 21, 2024 | markets.businessinsider.comModivCare is about to announce its earnings — here's what Wall Street expectsFebruary 21, 2024 | benzinga.comClearside Biomedical Stock (NASDAQ:CLSD), Short Interest ReportFebruary 18, 2024 | finance.yahoo.comCLSD Apr 2024 5.000 callFebruary 10, 2024 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Raised to "Hold" at StockNews.comStockNews.com upgraded shares of Clearside Biomedical from a "sell" rating to a "hold" rating in a report on Saturday.February 9, 2024 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Major Shareholder Buys $599,999.40 in StockClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) major shareholder Bradford T. Whitmore acquired 444,444 shares of the firm's stock in a transaction on Wednesday, February 7th. The shares were bought at an average cost of $1.35 per share, with a total value of $599,999.40. Following the completion of the acquisition, the insider now owns 4,495,034 shares in the company, valued at $6,068,295.90. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.February 9, 2024 | msn.comClearside Biomedical Launches $15M Direct Offering Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address WATCH: The Truth About Inflation (Ad)The full story on inflation is being CENSORED by the powers that be. But I have the REAL monthly numbers. And they are going to anger you. (Especially if you have money sitting in a 401k or IRA.) WATCH: The Truth About Inflation CLSD Media Mentions By Week CLSD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLSD News Sentiment▼0.360.55▲Average Medical News Sentiment CLSD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLSD Articles This Week▼302▲CLSD Articles Average Week Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Eton Pharmaceuticals News Today Aclaris Therapeutics News Today Oramed Pharmaceuticals News Today Anixa Biosciences News Today Milestone Pharmaceuticals News Today Adagene News Today BeyondSpring News Today ProPhase Labs News Today IO Biotech News Today Oncolytics Biotech News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLSD) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldDoes this make you sick?Allegiance GoldTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
